Immutep Limited
Save
–
Market cap
–
Current P/E
7.01x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.
Similar securities
Based on sector and market capitalization
Report issue